Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[99mTc]Tc-ZHER2:4107
- Development stage
- Phase 2
- Lead developer
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
[99mTc]Tc-ZHER2:4107 is a technetium-99m-labeled second-generation affibody molecule designed for the diagnostic imaging of HER2 expression in breast cancer patients using SPECT/CT. Developed by the Tomsk National Research Medical Center, it utilizes a small (6.5 kDa) non-immunoglobulin affinity protein scaffold (ZHER2:4107) engineered to bind with high affinity to the human epidermal growth factor receptor 2 (HER2). Unlike therapeutic HER2-targeted agents, this radiopharmaceutical is used as a diagnostic tool to visualize and quantify HER2 levels in primary tumors and metastases. It is particularly effective in discriminating between HER2-positive and HER2-low/negative expression, which is critical for selecting appropriate HER2-targeted therapies.
- Other names
- Technetium-99m-labeled Affibody ZHER2:410799mTc-labeled ZHER2:4107 affibody molecule
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on [99mTc]Tc-ZHER2:4107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [99mTc]Tc-ZHER2:4107.